BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 21571867)

  • 1. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
    Kim YJ; Yoon HY; Kim SK; Kim YW; Kim EJ; Kim IY; Kim WJ
    Clin Cancer Res; 2011 Jul; 17(13):4523-30. PubMed ID: 21571867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
    Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
    Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis.
    Nomoto S; Kanda M; Okamura Y; Nishikawa Y; Qiyong L; Fujii T; Sugimoto H; Takeda S; Nakao A
    Ann Surg Oncol; 2010 Mar; 17(3):923-32. PubMed ID: 19898900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation mediated silencing of TMS1/ASC gene in prostate cancer.
    Das PM; Ramachandran K; Vanwert J; Ferdinand L; Gopisetty G; Reis IM; Singal R
    Mol Cancer; 2006 Jul; 5():28. PubMed ID: 16848908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative assessment of AKAP12 promoter methylation in human prostate cancer using methylation-sensitive high-resolution melting: correlation with Gleason score.
    Liu W; Gong J; Hu J; Hu T; Sun Y; Du J; Sun C; Guan M; Jiang H; Lu Y
    Urology; 2011 Apr; 77(4):1006.e1-7. PubMed ID: 21310466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
    Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
    Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
    Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential.
    Almeida M; Costa VL; Costa NR; Ramalho-Carvalho J; Baptista T; Ribeiro FR; Paulo P; Teixeira MR; Oliveira J; Lothe RA; Lind GE; Henrique R; Jerónimo C
    J Cell Mol Med; 2014 Nov; 18(11):2287-97. PubMed ID: 25211630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
    Zhao H; Shiina H; Greene KL; Li LC; Tanaka Y; Kishi H; Igawa M; Kane CJ; Carroll P; Dahiya R
    Cancer; 2005 Jul; 104(1):44-52. PubMed ID: 15895377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
    Vanaja DK; Ballman KV; Morlan BW; Cheville JC; Neumann RM; Lieber MM; Tindall DJ; Young CY
    Clin Cancer Res; 2006 Feb; 12(4):1128-36. PubMed ID: 16489065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel tumor-suppressor gene epidermal growth factor-containing fibulin-like extracellular matrix protein 1 is epigenetically silenced and associated with invasion and metastasis in human gastric cancer.
    Zhu XJ; Liu J; Xu XY; Zhang CD; Dai DQ
    Mol Med Rep; 2014 Jun; 9(6):2283-92. PubMed ID: 24718752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer.
    Henrique R; Costa VL; Cerveira N; Carvalho AL; Hoque MO; Ribeiro FR; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    J Mol Med (Berl); 2006 Nov; 84(11):911-8. PubMed ID: 17016690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression.
    Lodygin D; Diebold J; Hermeking H
    Oncogene; 2004 Dec; 23(56):9034-41. PubMed ID: 15489902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors.
    Neumann O; Kesselmeier M; Geffers R; Pellegrino R; Radlwimmer B; Hoffmann K; Ehemann V; Schemmer P; Schirmacher P; Lorenzo Bermejo J; Longerich T
    Hepatology; 2012 Nov; 56(5):1817-27. PubMed ID: 22689435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
    Shames DS; Girard L; Gao B; Sato M; Lewis CM; Shivapurkar N; Jiang A; Perou CM; Kim YH; Pollack JR; Fong KM; Lam CL; Wong M; Shyr Y; Nanda R; Olopade OI; Gerald W; Euhus DM; Shay JW; Gazdar AF; Minna JD
    PLoS Med; 2006 Dec; 3(12):e486. PubMed ID: 17194187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
    Ellinger J; Haan K; Heukamp LC; Kahl P; Büttner R; Müller SC; von Ruecker A; Bastian PJ
    Prostate; 2008 Jan; 68(1):42-9. PubMed ID: 18004747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2'-deoxycytidine, microarray and gene expression profile.
    Khamas A; Ishikawa T; Shimokawa K; Mogushi K; Iida S; Ishiguro M; Mizushima H; Tanaka H; Uetake H; Sugihara K
    Cancer Genomics Proteomics; 2012; 9(2):67-75. PubMed ID: 22399497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer.
    Tokizane T; Shiina H; Igawa M; Enokida H; Urakami S; Kawakami T; Ogishima T; Okino ST; Li LC; Tanaka Y; Nonomura N; Okuyama A; Dahiya R
    Clin Cancer Res; 2005 Aug; 11(16):5793-801. PubMed ID: 16115918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.
    Avgeris M; Stravodimos K; Scorilas A
    Prostate; 2011 Dec; 71(16):1780-9. PubMed ID: 21520157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma.
    Dansranjavin T; Wagenlehner F; Gattenloehner S; Steger K; Weidner W; Dammann R; Schagdarsurengin U
    Prostate; 2012 Oct; 72(14):1550-8. PubMed ID: 22415519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.